Pancuronium pandemonium as doctors slam Hospira for execution injections
This article was originally published in Scrip
Executive Summary
An open letter published in the Lancet has criticised Hospira for its handling of the use of its muscle relaxant pancuronium bromide in executions in the US. However, Lundbeck, which faced a similar issue with its drug pentobarbital (Nembutal) for acute convulsive disorders, has emerged with its reputation intact. The letter praises the firm for its "truly exemplary" response to the situation after it tightened distribution of the drug.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.